| Parissa Razmjou, CRNA | |
|
5255 Loughboro Rd Nw, Washington, DC 20016-2633 | |
| (202) 537-4000 | |
| Not Available |
| Full Name | Parissa Razmjou |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 4 Years |
| Location | 5255 Loughboro Rd Nw, Washington, District Of Columbia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548747298 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sibley Memorial Hospital | Washington, DC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Surgical Anesthesia Associates Pllc | 5890739205 | 101 |
News Archive
New research presented at this year's annual meeting of the European Association for the Study of Diabetes in Barcelona, Spain (16-20 September) shows that specialist analysis of the lens in the eye can predict patients with type 2 diabetes and impaired glucose tolerance (IGT) (also known as prediabetes, a condition that often leads to full blown of type 2 diabetes).
Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy.
The MDI Biological Laboratory has announced that Sandra Rieger, Ph.D., has been awarded a highly competitive grant from the National Cancer Institute, an institute of the National Institutes of Health, to study the molecular mechanisms underlying chemotherapy-induced peripheral neuropathy, a side effect of cancer chemotherapy causing symptoms such as pain, tingling, temperature sensitivity and numbness in the extremities.
For the seventh consecutive year, Kaiser Permanente ranked highest in customer satisfaction for health insurance among California policyholders, according to ratings firm J.D. Power & Associates.
› Verified 8 days ago
| Entity Name | Surgical Anesthesia Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811930647 PECOS PAC ID: 5890739205 Enrollment ID: O20050616000610 |
News Archive
New research presented at this year's annual meeting of the European Association for the Study of Diabetes in Barcelona, Spain (16-20 September) shows that specialist analysis of the lens in the eye can predict patients with type 2 diabetes and impaired glucose tolerance (IGT) (also known as prediabetes, a condition that often leads to full blown of type 2 diabetes).
Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy.
The MDI Biological Laboratory has announced that Sandra Rieger, Ph.D., has been awarded a highly competitive grant from the National Cancer Institute, an institute of the National Institutes of Health, to study the molecular mechanisms underlying chemotherapy-induced peripheral neuropathy, a side effect of cancer chemotherapy causing symptoms such as pain, tingling, temperature sensitivity and numbness in the extremities.
For the seventh consecutive year, Kaiser Permanente ranked highest in customer satisfaction for health insurance among California policyholders, according to ratings firm J.D. Power & Associates.
› Verified 8 days ago
| Entity Name | Metromac Anesthesiology, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437456951 PECOS PAC ID: 0648455097 Enrollment ID: O20110428000214 |
News Archive
New research presented at this year's annual meeting of the European Association for the Study of Diabetes in Barcelona, Spain (16-20 September) shows that specialist analysis of the lens in the eye can predict patients with type 2 diabetes and impaired glucose tolerance (IGT) (also known as prediabetes, a condition that often leads to full blown of type 2 diabetes).
Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy.
The MDI Biological Laboratory has announced that Sandra Rieger, Ph.D., has been awarded a highly competitive grant from the National Cancer Institute, an institute of the National Institutes of Health, to study the molecular mechanisms underlying chemotherapy-induced peripheral neuropathy, a side effect of cancer chemotherapy causing symptoms such as pain, tingling, temperature sensitivity and numbness in the extremities.
For the seventh consecutive year, Kaiser Permanente ranked highest in customer satisfaction for health insurance among California policyholders, according to ratings firm J.D. Power & Associates.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Parissa Razmjou, CRNA 1210 R St Nw Apt B11, Washington, DC 20009-4127 Ph: (508) 404-7595 | Parissa Razmjou, CRNA 5255 Loughboro Rd Nw, Washington, DC 20016-2633 Ph: (202) 537-4000 |
News Archive
New research presented at this year's annual meeting of the European Association for the Study of Diabetes in Barcelona, Spain (16-20 September) shows that specialist analysis of the lens in the eye can predict patients with type 2 diabetes and impaired glucose tolerance (IGT) (also known as prediabetes, a condition that often leads to full blown of type 2 diabetes).
Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy.
The MDI Biological Laboratory has announced that Sandra Rieger, Ph.D., has been awarded a highly competitive grant from the National Cancer Institute, an institute of the National Institutes of Health, to study the molecular mechanisms underlying chemotherapy-induced peripheral neuropathy, a side effect of cancer chemotherapy causing symptoms such as pain, tingling, temperature sensitivity and numbness in the extremities.
For the seventh consecutive year, Kaiser Permanente ranked highest in customer satisfaction for health insurance among California policyholders, according to ratings firm J.D. Power & Associates.
› Verified 8 days ago
Miss Ore-oluwa Odulana Lima Da Silva, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 110 Irving St Nw, Washington, DC 20010 Phone: 202-877-7504 | |
Kathryn T Turner, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 110 Irving St Nw, Washington, DC 20010 Phone: 301-946-5100 Fax: 301-929-0348 | |
Glenise Lynn Sanchez Perez, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 110 Irving St Nw, Washington, DC 20010 Phone: 202-877-7000 | |
Barbara Pursell, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 3800 Reservoir Rd Nw, Washington, DC 20007 Phone: 202-444-4904 | |
Vera Tantoco, Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 3800 Reservoir Rd Nw, Washington, DC 20007 Phone: 202-444-8640 | |
Donna Jasinski, Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 3800 Reservoir Rd Nw, Washington, DC 20007 Phone: 202-444-8640 | |
Ms. Jane Ann Skelton, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 110 Irving St Nw, Dept. Anesthesia Angie Edwards, Washington, DC 20016 Phone: 202-877-7000 |